Leukemic Phase of ALCL

Anaplastic Lymphoma Clinical Trial

— LEUK-ALCL  

Official title:

Leukemic Phase of ALK+ Anaplastic Lymphoma in Real-life Practice: Experience of a University Clinical Hematology Laboratory

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04908059
• Other study ID #: 8115
• Status: Recruiting
• Start date: January 27, 2021
• Est. completion date: July 13, 2021

Study information

• Verified date: May 2021
• Source: University Hospital, Strasbourg, France
• Contact: Laurent MAUVIEUX, MD, PhD
• Phone: 33 3 88 12 75 27
• Email: laurent.mauvieux[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2
• Est. completion date: July 13, 2021
• Est. primary completion date: July 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 9 Years and older

Eligibility

Inclusion Criteria:

• Patients presenting a leukemic phase of anaplastic lymphoma

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Anaplastic Lymphoma
• Lymphoma

Locations

Country	Name	City	State
France	Hematology Laboratory - Strasbourg University Hospitals	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A retrospective study of the diagnostic description of the leukemic phases of anaplastic lymphoma in real life		Files analysed retrospectively from January 01, 2020 to December 31, 2020 will be examined]